Neuromodulation
Neuromodulation is the physiological process by which a given neuron uses one or more chemicals to regulate diverse populations of neurons. Neuromodulators typically bind to metabotropic, G-protein coupled receptors to initiate a second messenger signaling cascade that induces a broad, long-lasting signal. This modulation can last for hundreds of milliseconds to several minutes. Some of the effects of neuromodulators include: alter intrinsic firing activity, increase or decrease voltage-dependent currents, alter synaptic efficacy, increase bursting activity and reconfiguration of synaptic connectivity.
Major neuromodulators in the central nervous system include: dopamine, serotonin, acetylcholine, histamine, norepinephrine and several neuropeptides. Neuromodulators can be packaged into vesicles and released by neurons, secreted as hormones and delivered through the circulatory system. A neuromodulator can be conceptualized as a neurotransmitter that is not reabsorbed by the pre-synaptic neuron or broken down into a metabolite. Some neuromodulators end up spending a significant amount of time in the cerebrospinal fluid, influencing the activity of several other neurons in the brain.
Neuromodulatory systems
The major neurotransmitter systems are the noradrenaline system, the dopamine system, the serotonin system, and the cholinergic system. Drugs targeting the neurotransmitter of such systems affects the whole system, and explains the mode of action of many drugs.Most other neurotransmitters, on the other hand, e.g. glutamate, GABA and glycine, are used very generally throughout the central nervous system.
System | Origin | Targets | Effects |
Noradrenaline system | Locus coeruleus | Adrenergic receptors in:
| |
Noradrenaline system | Lateral tegmental field | ||
Dopamine system | Dopamine pathways: | Dopamine receptors at pathway terminations. | |
Serotonin system | caudal dorsal raphe nucleus | Serotonin receptors in: | |
Serotonin system | rostral dorsal raphe nucleus | Serotonin receptors in: | |
Cholinergic system | Pedunculopontine nucleus and dorsolateral tegmental nuclei | M1 receptors in: | |
Cholinergic system | basal optic nucleus of Meynert | M1 receptors in: | |
Cholinergic system | medial septal nucleus | M1 receptors in: |
Noradrenaline system
The noradrenaline system consists of just 1500 neurons on each side of the brain, primarily in the locus coeruleus. This is diminutive compared to the more than 100 billion neurons in the brain. As with dopaminergic neurons in the substantia nigra, neurons in the locus coeruleus tend to be melanin-pigmented. Noradrenaline is released from the neurons, and acts on adrenergic receptors. Noradrenaline is often released steadily so that it can prepare the supporting glial cells for calibrated responses. Despite containing a relatively small number of neurons, when activated, the noradrenaline system plays major roles in the brain including involvement in suppression of the neuroinflammatory response, stimulation of neuronal plasticity through LTP, regulation of glutamate uptake by astrocytes and LTD, and consolidation of memory.Dopamine system
The dopamine or dopaminergic system consists of several pathways, originating from the ventral tegmentum or substantia nigra as examples. It acts on dopamine receptors.Parkinson's disease is at least in part related to dropping out of dopaminergic cells in deep-brain nuclei, primarily the melanin-pigmented neurons in the substantia nigra but secondarily the noradrenergic neurons of the locus coeruleus. Treatments potentiating the effect of dopamine precursors have been proposed and effected, with moderate success.
Dopamine pharmacology
- Cocaine, for example, blocks the reuptake of dopamine, leaving these neurotransmitters in the synaptic gap longer.
- AMPT prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine; reserpine prevents dopamine storage within vesicles; and deprenyl inhibits monoamine oxidase -B and thus increases dopamine levels.
Serotonin system
Serotonin pharmacology
- Selective serotonin reuptake inhibitors such as fluoxetine are widely used antidepressants that specifically block the reuptake of serotonin with less effect on other transmitters.
- Tricyclic antidepressants also block reuptake of biogenic amines from the synapse, but may primarily effect serotonin or norepinephrine or both. They typically take 4 to 6 weeks to alleviate any symptoms of depression. They are considered to have immediate and long-term effects.
- Monoamine oxidase inhibitors allow reuptake of biogenic amine neurotransmitters from the synapse, but inhibit an enzyme which normally destroys some of the transmitters after their reuptake. More of the neurotransmitters are available for release into synapses. MAOIs take several weeks to alleviate the symptoms of depression.
Cholinergic system
The cholinergic system consists of projection neurons from the pedunculopontine nucleus, laterodorsal tegmental nucleus, and basal forebrain and interneurons from the striatum and nucleus accumbens. It is not yet clear whether acetylcholine as a neuromodulator acts through volume transmission or classical synaptic transmission, as there is evidence to support both theories. Acetylcholine binds to both metabotropic muscarinic receptors and the ionotropic nicotinic receptors. The cholinergic system has been found to be involved in responding to cues related to the reward pathway, enhancing signal detection and sensory attention, regulating homeostasis, mediating the stress response, and encoding the formation of memories.GABA
has an inhibitory effect on brain and spinal cord activity.Neuropeptides
s are small proteins used for communication in the nervous system. Neuropeptides represent the most diverse class of signaling molecules. There are 90 known genes that encode human neuropeptide precursors. In invertebrates, there are ~50 known genes encoding neuropeptide precursors. Most neuropeptides bind to G-protein coupled receptors, however some neuropeptides directly gate ion channels or act through kinase receptors.- Opioid peptides – a large family of endogenous neuropeptides that are widely distributed throughout the central and peripheral nervous system. Opiate drugs such as heroin and morphine act at the receptors of these neurotransmitters.
- Endorphins
- Enkephalins
- Dynorphins
- Vasopressin
- Oxytocin
- Gastrin
- Cholecystokinins
- Somatostatin
- Cortistatins
- RF-amides
- Neuropeptide FF
- Neuropeptide Y -
- Pancreatic Polypeptide
- Peptide YY
- Prolactin-releasing peptide
- Calcitonin
- Adrenomedullin
- Natriuretic
- Bombesin-like peptides
- Endothelin
- Glucagon
- Secretin
- Vasoactive Intestinal Peptide
- Growth Hormone Releasing Hormone
- Gastric Inhibitory Peptide
- Corticotropin Releasing Hormone
- Urocortin
- Urotensin
- Substance P
- Neuromedins
- Tensin
- Kinin
- Granin
- Nerve Growth Factor
- Motilin
- Ghrelin
- Galanin
- Neuropeptide B/W
- Neurexophilin
- Insulin
- Relaxin
- Agouti-related protein homolog gene
- Prolactin
- Apelin
- Metastasis-suppressor
- Diazepam-binding inhibitor
- Cerebellins
- Leptin
- Adiponectin
- Visfatin
- Resistin
- Nucleibindin
- Ubiquitin
Neuromuscular systems